Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-Current Deffered Revenue (2016 - 2020)

Karyopharm Therapeutics' Non-Current Deffered Revenue history spans 7 years, with the latest figure at $2.2 million for Q1 2020.

  • For Q1 2020, Non-Current Deffered Revenue fell 32.45% year-over-year to $2.2 million; the TTM value through Mar 2020 reached $2.2 million, down 32.45%, while the annual FY2019 figure was $2.2 million, 51.63% down from the prior year.
  • Non-Current Deffered Revenue reached $2.2 million in Q1 2020 per KPTI's latest filing, roughly flat from $2.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $4.5 million in Q2 2018 to a low of $1.4 million in Q4 2017.
  • Average Non-Current Deffered Revenue over 5 years is $2.5 million, with a median of $2.2 million recorded in 2018.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 232.5% in 2018, then crashed 51.63% in 2019.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $1.7 million in 2016, then fell by 18.19% to $1.4 million in 2017, then surged by 232.5% to $4.5 million in 2018, then plummeted by 51.63% to $2.2 million in 2019, then changed by 0.0% to $2.2 million in 2020.
  • Per Business Quant, the three most recent readings for KPTI's Non-Current Deffered Revenue are $2.2 million (Q1 2020), $2.2 million (Q4 2019), and $3.5 million (Q3 2019).